An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake.
BlackRock, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Arcutis Biotherapeutics, Inc. (ARQT), reporting a beneficial ownership of 14.1% of the class, totaling 17,751,435 shares. The filing indicates BlackRock holds sole voting power over 17,576,492 shares and sole dispositive power over 17,751,435 shares. Additionally, the iShares Core S&P Small-Cap ETF is identified as having an interest exceeding 5% in ARQT's outstanding common stock.
Arcutis Biotherapeutics, Inc. (ARQT) stock price, news, quote and history
This page provides comprehensive information on Arcutis Biotherapeutics, Inc. (ARQT), including its current stock price, historical data, financial performance, and recent news. The company focuses on dermatological treatments with its lead product ZORYVE and has seen a positive 1-year return of 18.40%. Analyst ratings indicate a strong buy consensus with an average price target of $37.00.
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals
Arcutis Biotherapeutics (NASDAQ:ARQT) is highlighted for its strong growth and improving fundamentals, aligning with Louis Navellier's eight rules for growth investing. The company shows significant positive earnings revisions, repeated earnings surprises, increasing sales growth, and expanding margins, driven by its ZORYVE franchise. While presenting a promising growth profile and strong valuation against peers, the article also notes risks such as high absolute valuation, past negative net income, and commercial execution challenges in a competitive market.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial information for Arcutis Biotherapeutics, Inc. (ARQT), including its current stock price, historical data, key statistics, performance overview, earnings trends, and analyst ratings. The company focuses on developing and commercializing treatments for dermatological diseases, with its lead product being ZORYVE.
Arcutis Taps Gymnast Simone Biles for New Seb Derm and Eczema Awareness Campaign
World Champion gymnast Simone Biles has partnered with Arcutis Biotherapeutics to launch the "Skin to Believe In" awareness campaign, encouraging individuals with inflammatory skin conditions to discuss steroid-free topical treatment options with their doctors. Biles shared her personal journey with seborrheic dermatitis and eczema, highlighting her successful experience with Arcutis' ZORYVE foam and cream after trying various over-the-counter products. Dermatologist Angela J. Lamb, MD, also endorsed ZORYVE, emphasizing its benefits as a once-daily, steroid-free PDE4 inhibitor for long-term management of chronic skin conditions.
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Gymnast Simone Biles has partnered with Arcutis Biotherapeutics to launch the "Skin to Believe In" awareness campaign, aiming to educate people about seborrheic dermatitis and eczema. Biles shares her personal experience managing these conditions with ZORYVE, a steroid-free topical treatment. The campaign encourages individuals with inflammatory skin conditions to consult healthcare providers for long-term treatment options and helps destigmatize chronic skin issues.
Trading Systems Reacting to (ARQT) Volatility
This article analyzes Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) volatility, noting strong near and mid-term sentiment that could extend long-term. It identifies a mid-channel oscillation pattern and an exceptional 58.1:1 risk-reward setup targeting a 16.1% gain. The piece outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to optimize trading decisions.
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 600
Arcutis Biotherapeutics, Inc. (NasdaqGS: ARQT) has been added to the S&P 600 index. The company is a commercial-stage medical dermatology company with a portfolio including ZORYVE Roflumilast Cream and Foam, and ARQ-234, targeting various inflammatory dermatological conditions. Analyst consensus rates ARQT as a "BUY" with an average target price of $37.00.
Arcutis Biotherapeutics Inc. (ARQT) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Arcutis Biotherapeutics Inc. (ARQT) stock on NASDAQ, showing a current price of $26.16 with a 5.83% decrease. It also notes that there is no current analyst rating or earnings information available for the company. The article includes general disclaimers about the risks and low profitability of day trading.
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares
Masaru Matsuda, EVP and Chief Legal Officer at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 3,674 shares of the company's common stock for approximately $91,853 on September 16, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The sale occurred while ARQT stock has delivered a 49% return over the past year and recently reported a significant increase in Q2 2026 revenue, reaching $129.9 million, exceeding market forecasts and moving the company into profitability.
Arcutis Biotherapeutics EVP Masaru Matsuda Sells 3,674 Shares Under 10b5-1 Plan
Masaru Matsuda, EVP and Chief Legal Officer of Arcutis Biotherapeutics (NASDAQ:ARQT), sold 3,674 shares of the company's common stock on September 16, 2026. The transaction was executed under a Rule 10b5-1 trading plan adopted on June 5, 2026, at a weighted average price of $25.0009 per share. Following the sale, Matsuda beneficially owns 112,508 shares.
Arcutis Biotherapeutics (NASDAQ: ARQT) director plans $114K stock sale
Arcutis Biotherapeutics director Howard Welgus filed a Rule 144 notice to sell 4,730 shares of ARQT common stock, valued at approximately $114,000. This filing indicates a planned sale through a brokerage firm on NASDAQ and provides details on past sales by Welgus as well as key figures and terms related to the transaction.
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%
Arcutis Biotherapeutics stock jumped 11.19% after CEO Frank Watanabe reiterated confidence in their ZORYVE psoriasis and dermatitis franchise at a Morgan Stanley conference, projecting $2.5 billion to $3 billion in peak sales. The stock's rise, however, occurred on low trading volume, suggesting existing shareholders' conviction rather than new institutional buying. TIKR's model values the stock significantly higher at $102 by 2030, based on anticipated ZORYVE market penetration exceeding analyst expectations.
Former Arcutis (NASDAQ: ARQT) officer plans multimillion-dollar stock sale
A former officer of Arcutis Biotherapeutics, Larry Todd Edwards, has filed a Rule 144 notice to sell up to 341,980 shares of ARQT common stock, valued at approximately $8.5 million. These shares originate from various stock option exercises between 2023 and 2026. The proposed sale, set to occur through Merrill Lynch on or after September 16, 2026, represents a small fraction of the 125,691,961 outstanding shares.
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock
Masaru Matsuda, EVP and Chief Legal Officer at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 9,989 shares worth approximately $249,985 on September 8, 2026, under a pre-arranged trading plan. This sale occurred as ARQT stock trades at $23.38, down 19% year-to-date but up 32% over the past year. The company recently reported strong Q2 2026 financial results, with net product revenue surging to $129.9 million, exceeding forecasts and leading to profitability and a raised price target from Guggenheim.
Arcutis (ARQT) officer lines up Rule 144 stock sale
Arcutis Biotherapeutics, Inc. (ARQT) officer Masaru Matsuda plans to sell 13,663 shares of common stock, valued at $341,933, through Merrill Lynch around September 8, 2026, under Rule 144. The shares originate from multiple restricted stock vesting events between May 2024 and August 2025. This filing also reports a prior sale of 1,230 shares on August 3, 2026, for $32,123.66.
Arcutis Biotherapeutics Updates ZORYVE Prescribing Information for Aerosol and Foam Formulations
Arcutis Biotherapeutics has updated the prescribing information for its ZORYVE medication, available in aerosol and foam formulations. The updated documentation, released on September 4, 2026, details the clinical specifications and usage guidelines for these products in the DailyMed database. This information provides comprehensive data on the administration and chemical composition of the roflumilast-based treatments for healthcare providers.
(ARQT) as a Liquidity Pulse for Institutional Tactics
This article analyzes Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) using AI models to provide institutional trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, offering specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies. The analysis identifies an exceptional short setup with a high risk-reward ratio.
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced that its management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14-16, 2026, in New York. The company will hold a fireside chat on Wednesday, September 16, 2026, at 1:50 p.m. ET, with a webcast available through their website for 180 days. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a portfolio of treatments for chronic inflammatory skin diseases.
Arcutis director Terrie Curran sells $956k in shares
Arcutis Biotherapeutics director Terrie Curran sold 38,200 shares of the company's stock for a total of $956,122 on August 27, 2026, after exercising stock options. Following these transactions, Curran now beneficially owns 23,526 shares. This insider sale comes amidst strong financial performance for Arcutis, including a significant increase in Q2 2026 revenue and profitability driven by its product Zoryve.
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?
Arcutis Biotherapeutics (ARQT) has experienced recent share price fluctuations, with a 12% drop over the last month but a 16% increase over the past three months. While a detailed revenue and earnings forecast suggests the company is undervalued at $36.88 per share compared to its $24.87 close, its current P/E ratio of 109.6x is significantly higher than peers, indicating potential valuation risk. Investors are encouraged to review the underlying numbers and consider risks related to its key product ZORYVE's performance and payer support.
Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K
Arcutis Biotherapeutics Board Member Terrie Curran exercised stock options for 1,072 shares of ARQT, valued at $18,642, as revealed in an SEC filing on August 24. The company's stock was up by 0.81% at $24.9 following the transaction. The article also provides an analysis of Arcutis Biotherapeutics' financial performance, highlighting strong revenue growth and gross margin but noting challenges in EPS and debt management.
Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026
Arcutis Biotherapeutics Director Terrie Curran executed stock options for 1,072 shares at $7.51 per share and simultaneously sold all these shares at a weighted average price of $26.0376 on August 20, 2026. Following these transactions, Curran's direct beneficial ownership in Arcutis Biotherapeutics (NASDAQ:ARQT) is 23,526 shares, and she retains 11,148 stock options expiring in 2033. The transactions were detailed in a Form 4 filed with the SEC on August 24, 2026.
Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT
Tejara Capital Ltd has acquired a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), purchasing 113,084 shares valued at approximately $2.965 million, making it their 24th biggest holding. Several other hedge funds also adjusted their stakes in ARQT, while company insiders sold shares totaling over $288,000. Analyst ratings indicate a "Moderate Buy" consensus with an average price target of $35.57.
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares
A director at Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), Terrie Curran, has filed a Rule 144 notice to sell 1,072 shares of the company's common stock. These shares, valued at $27,912.35, were acquired through a stock option exercise on May 31, 2023, and are planned to be sold via Merrill Lynch on the NASDAQ. This filing indicates an insider transaction and is considered to have a neutral impact and sentiment.
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares
Arcutis Biotherapeutics Director Howard Welgus sold 4,730 shares of the company's stock for $123,831.40, reducing his ownership by 11.48%. This transaction occurred under a Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings of $0.11 per share and revenue of $129.86 million, both exceeding analyst expectations.
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades
Arcutis Biotherapeutics officer Patrick Burnett plans to sell 1,697 shares of common stock, valued at approximately $45,819, as detailed in a recent SEC Form 144 filing. This proposed sale follows prior transactions in August where Burnett sold significant blocks of shares. The filing also notes that the shares are associated with a restricted stock vest on August 18, 2026.
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale
Howard Welgus has filed a Form 144 indicating an upcoming sale of 4,730 shares of Arcutis Biotherapeutics (NASDAQ: ARQT) common stock, valued at $123,834.71, through Merrill Lynch on or after August 17, 2026. These shares are linked to restricted stock vesting and stock option exercises from various dates. Welgus has also reported several sales of ARQT shares in the preceding three months.
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action?
Arcutis Biotherapeutics (ARQT) reported strong Q2 2026 results with $129.86 million in revenue and $15.01 million in net income, leading management to raise full-year 2026 net product sales guidance to $525 million–$540 million. This performance, coupled with the chief commercial officer's resignation, reinforces confidence in ZORYVE's uptake and suggests Arcutis's commercial execution is ahead of schedule. While the higher sales outlook is positive, investors should consider the company's concentrated revenue base, potential generic pressure, and narrow internal pipeline when evaluating its long-term growth durability.
Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G
Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as of May 6, 2026. This filing indicates a passive investment intent, with the aggregated amount beneficially owned representing 5.28% of the class.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 million. Despite positive analyst sentiment and strong financial performance, company insiders have sold approximately $803,066 worth of shares in the past 90 days.
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock
Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ: ARQT), sold $394,896 worth of company stock across two transactions on August 11 and 12, 2026, after exercising stock options. These sales occurred at weighted average prices around $26.52 and $26.08, following options exercised at $3.64 per share. Arcutis Biotherapeutics recently reported strong Q2 2026 financial results, with net product revenue exceeding forecasts, leading Guggenheim to raise its price target for the company.
Patrick Burnett Sells 8,300 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 8,300 shares of the company's stock on August 11th at an average price of $26.52, totaling $220,116. This transaction reduced his ownership by 6.51% and follows other sales in early August. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating with a target price of $35.57, driven by recent quarterly results that exceeded revenue and EPS expectations.
Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the insider selling, analyst sentiment for ARQT remains positive with a "Moderate Buy" consensus and an average price target of $35.57, driven by recent quarterly results that exceeded expectations.
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com
Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 results showed a significant revenue increase, leading Guggenheim to raise its price target. Arcutis Biotherapeutics appears undervalued according to InvestingPro analysis, despite a strong gross profit margin.
Bank of America Corp DE Acquires 547,835 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Bank of America Corp DE significantly increased its stake in Arcutis Biotherapeutics by 32.7%, acquiring an additional 547,835 shares, bringing its total to 2.22 million shares valued at $52.3 million. This move comes as analysts maintain a "Moderate Buy" rating for ARQT, with several firms raising their price targets following strong Q1 earnings where the company surpassed revenue and EPS expectations. Other institutional investors have also increased their positions in Arcutis, despite some insider selling activity.
Arcutis insider plans sale of 15,000 shares | ARQT SEC Filing - Form 144
Arcutis Biotherapeutics (ARQT) insider Patrick Burnett has filed a Form 144 to sell 15,000 shares of common stock through Merrill Lynch on or after August 11, 2026. These shares were acquired via a stock option exercise on January 12, 2024. Burnett previously sold 955 shares on August 3, 2026, for $24,941.54.
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Biotherapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides an overview of the company's financial performance during this period. Readers can access the full report for more detailed financial information.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics announced the grant of 143,500 restricted stock units (RSUs) and options to purchase 37,000 shares to 24 new employees. These inducement awards were made under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 3, 2026. The RSUs and stock options will vest over four years, subject to continued employment, and the stock options have an exercise price of $25.94 per share.
State Street Corporation (ARQT) discloses 4.7% beneficial stake in Arcutis
State Street Corporation has disclosed a 4.7% beneficial ownership stake in Arcutis Biotherapeutics, Inc., amounting to 5,822,840 shares. The filing, a SCHEDULE 13G, indicates that State Street and its investment adviser affiliates collectively manage these shares with shared voting power over 5,507,182 shares and shared dispositive power over all 5,822,840 shares. This disclosure falls under the "ownership of 5 percent or less of a class" category, with Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer, signing the report.
24 New Arcutis Employees Get Stock Awards That Vest Over Four Years
Arcutis Biotherapeutics (Nasdaq: ARQT) has granted 143,500 restricted stock units (RSUs) and options to purchase 37,000 shares to 24 new hires. These inducement grants, effective August 3, 2026, vest over four years, subject to continued employment, and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term with an exercise price of $25.94 per share, matching the closing price on August 3, 2026.
Arcutis Biotherapeutics, Inc. 2026: Revenue $129.86M, EPS $0.11— 10-Q Summary
Arcutis Biotherapeutics, Inc. reported strong results for the 2026 quarter, with revenue reaching $129.86M and diluted EPS at $0.11, significantly exceeding the prior year's performance. The growth was primarily driven by increased product demand, successful label expansions, and a strategic shift to an internal commercial team. The company also saw substantial year-to-date product net sales growth and positive clinical pipeline advancements.
Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $36.62, Implies 35% Upside
Arcutis Biotherapeutics, Inc. (ARQT) has seen its average 12-month price target raised from $34.62 to $36.62 by 8 analysts, suggesting a 35% potential upside from its August 5 closing price. The consensus rating for ARQT remains "Buy," with 7 Buys and 1 Hold among covering analysts.
Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?
Arcutis Biotherapeutics (ARQT) recently announced its chief commercial officer's resignation, yet reported strong second-quarter 2026 revenue of US$129.86 million and net income of US$15.01 million, alongside raising its full-year 2026 net product sales guidance to US$525 million–US$540 million. The company is also bringing in Robert Lisicki, an experienced commercial leader, suggesting a shift in its investment narrative towards sustained ZORYVE expansion and profitability despite concentration risk. Analysts project significant revenue and earnings growth by 2029, with a fair value estimate indicating a potential 28% upside.
Arcutis Biotherapeutics EVP Burnett sells $24,941 in stock
Patrick Burnett, EVP and Chief Medical Officer at Arcutis Biotherapeutics (NASDAQ: ARQT), sold 955 shares of company stock for $24,941 to cover tax withholding obligations. The sale occurred on August 3, 2026, at an average price of $26.1168 per share. Despite this sale, ARQT shares have seen a strong 76% return over the past year, and the company recently reported increased Q2 revenue and profitability.
Form 4 Arcutis Biotherapeutics Inc For: 6 August By Investing.com
This article reports on the filing of Form 4 for Arcutis Biotherapeutics Inc. on August 6, 2026. Form 4 filings disclose changes in beneficial ownership of company securities by insiders. The brief news item indicates that this information was published by Investing.com.
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Arcutis President and CEO Todd Watanabe sold 4,375 shares for $114,275 on August 3, 2026. This transaction was non-discretionary, executed to cover tax obligations from vested restricted stock units, and does not reflect a change in his outlook for the company. Arcutis Biotherapeutics reported profitability in Q2 2026 with a net income of $15 million and raised its full-year 2026 net product sales guidance.
Earnings call transcript: Arcutis Biotherapeutics tops Q2 2026 revenue view
Arcutis Biotherapeutics reported strong Q2 2026 results, surpassing revenue expectations and achieving profitability due to robust demand for its dermatology product, ZORYVE. The company raised its full-year 2026 revenue guidance to $525 million-$540 million, driven by continued prescription growth, recent FDA approvals for ZORYVE in pediatric psoriasis, and strategic investments in sales force expansion and patient access initiatives. Arcutis also highlighted progress in its pipeline, including trials for vitiligo and hidradenitis suppurativa, and the advancement of ARQ-234 for atopic dermatitis.
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary
Arcutis Biotherapeutics, Inc. reported a significant turnaround in Q2 2026, with a 59% year-over-year revenue increase driven by strong ZORYVE franchise demand and the successful conversion from topical steroids. The company raised its full-year sales guidance to $525 million–$540 million, expecting continued growth from sales force expansion, a new primary care team, and a virtual health platform. Arcutis also achieved positive net income and is pursuing pipeline expansion and a PDUFA date for ZORYVE cream in infants.
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics (ARQT) reported Q2 earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09, and revenues of $129.86 million, surpassing estimates by 6.57%. Despite the strong quarterly performance, the stock has underperformed the S&P 500 year-to-date. The company currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance.
